Trailing Twelve Month EBITDA. EBITDA at not less than the amounts set forth below at the indicated dates, measured as of the end of each fiscal quarter for the 12 months then-ending, as follows: Fiscal Quarter Date Minimum EBITDA Amount June 30, 2010 $3,500,000.00 September 30, 2010 and thereafter $4,000,000.00
Trailing Twelve Month EBITDA. (of Resmed and RMT)
Trailing Twelve Month EBITDA. Commencing on the Closing Date and ending on December 31, 2024, the Borrowers shall maintain EBITDA (on a trailing basis beginning with the month ending September 30, 2023, and as of the August 30, 2024 measurement period and all future periods, on a trailing twelve-month basis) in accordance with the schedule immediately below: September 30th 2023 US $141,662.52 October 31st 2023 US $544,723.34 November 30th 2023 US $904,951.74 December 31st 2023 US $1,052,705.73 January 31st 2024 US $1,455,422.43 February 29th 2024 US $1,928,944.68 March 30th 2024 US $2,388,870.87 April 30th 2024 US $2,873,709.93 May 31st 2024 US $3,428,882.94 June 30th 2024 US $3,954,979.93 July 31st 2024 US $4,492,420.78 August 31st 2024 US $5,047,190.73 September 30th 2024 US $5,388,550.09 October 31st, 2024 US $5,561,637.25 November 30th 2024 US $5,846,881.04 December 31st 2024 US $6,236,869.98 If the trailing-twelve month EBITDA falls below the scheduled thresholds above, the Loan Parties shall cause BBX Capital, Inc. to immediately provide a Permitted Financial Covenant Equity Contribution. It is agreed that any Permitted Financial Covenant Equity Contribution shall be included for purposes of the calculation of Excess Availability and compliance with subsection 12(q) under this Agreement.
